Drugs / cAd3-Marburg
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 21 trial | ||||||
| Phase 2 | NCT05817422 | Oct 2023 → Apr 2025 | Marburg hemorrhagic fever | Albert B. Sabin Vaccine Institute | Completed | No outcome recorded |
| Comparator or background therapy1 trial | ||||||
| Phase 1 | NCT04723602 Comparator | Jan → Dec 2021 | Ebola hemorrhagic fever, Marburg hemorrhagic fever | Albert B. Sabin Vaccine Institute | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | cAd3 Marburg | “Monovalent Chimpanzee Adenoviral Vectored Filovirus (Marburg) (cAd3 Marburg) vaccines” NCT04723602 ↗ |
| Modality | Vaccine | “2 Monovalent Chimpanzee Adenoviral Vectored Filovirus (Ebola-S and Marburg) Vaccines” NCT04723602 ↗ |
| Route | Intramuscular | “intramuscularly in deltoid muscle” NCT05817422 ↗ |